Time To Add.Maybe I'm overly optomistic but I feel that we may be on the cusp of something pretty good.
A couple of points. First, at the very bottom of the release, they make the statement: This press release does not express or imply that the Company claims it's product has the ablilty to eliminate, cure, or contain the SARS-2-CoV-2 [ COVID 19]. This statement would have been sufficient had they ended it there, but they didn't. Instead they added the words, "at this time". To me , the inference is,"stay tuned, we may want to change that".
Secondly, in the last paragraph under pipeline they say," Yeast beta glucan to become a key product of Ceapro's portfolio." Many companies sell YBG and as far as we know we have not as yet sold any of ours to anyone. So, for them to make a statement like that , they must be aware of some benefit or unique property of Ceapro's YBG that we shareholders are not yet aware of. Gagnon has gone so far in the past to refer to PGX-YBG as the,'masterpiece" of Ceapro's strategy. To make that statement essentialy before we have made our first sale of PGX-YBG to me says they must really feel they are on to something big.
I will be adding as cash becomes available. GLTA.